U.S. Medical
This site is intended for U.S. Healthcare Professionals.
To report an adverse event or product quality complaint, call 1-877-TAKEDA-7 (1-877-825-3327)
This site is intended for U.S. Healthcare Professionals.
To report an adverse event or product quality complaint, call 1-877-TAKEDA-7 (1-877-825-3327)
Not an actual patient.
ADHD is a complex, heterogeneous disorder affecting individuals over the course of their lifetime.1 Symptoms of ADHD begin before age 12 and interfere with functioning or development.
ADHD affects approximately 11% of school-aged children in the U.S., based on the 2011 National Survey of Children’s Health, in which parents were asked if a healthcare practitioner had ever told them their child had ADD or ADHD.2
The estimated prevalence of adult ADHD in the U.S. is 4.4%.3 This is based on results from semi-structured clinical interviews conducted in 3,199 respondents aged 18-44 in the National Comorbidity Survey Replication (from 2001 to 2003).
Estimates of the prevalence of ADHD vary due to different research methodologies, varying age groups in epidemiological studies, and changes in the diagnostic criteria over time.4
The American Academy of Child and Adolescent Psychiatry recommends that screening for ADHD should be a part of every patient’s mental health assessment, and the American Academy of Pediatrics recommends initiating an evaluation for ADHD in school-aged children who present with academic or behavioral problems and symptoms of inattention and/or hyperactivity-impulsivity.4,5
For a diagnosis of ADHD, individuals must meet the DSM-5 criteria.1 According to the DSM-5, an individual must show at least 6 symptoms of inattention and/or at least 6 symptoms of hyperactivity-impulsivity that must have persisted for at least 6 months to a degree that is inconsistent with the developmental level and negatively impacts social, academic, and/or occupational activities. In individuals 17 years or older, at least 5 symptoms of inattention and/or at least 5 symptoms of hyperactivity-impulsivity must be present.
| DSM-5 Symptoms of Inattention Symptoms must occur often | DSM-5 Symptoms of Hyperactivity and Impulsivity Symptoms must occur often |
|---|---|
| Fails to give close attention to detail, or makes careless mistakes | Fidgets, squirms, or taps hands or feet |
| Has difficulty sustaining attention in tasks or play | Leaves seat when sitting is expected |
| Does not seem to listen when spoken to directly | Runs around or climbs when it is not appropriate |
| Does not follow through on instructions and fails to finish chores, homework, or work duties | Unable to play or engage in leisure activities quietly |
| Shows difficulty in organizing tasks | Acts “as if driven by a motor” / is "on the go" |
| Avoids, dislikes, or is reluctant to engage in activities that require sustained mental effort | Talks excessively |
| Loses things needed for tasks or activities | Answers questions before the question is fully asked |
| Is easily distracted | Has difficulty waiting for a turn or waiting in lines |
| Is forgetful in daily activities | Interrupts or intrudes on others |
Additionally, to meet the DSM-5 diagnostic criteria, several of the symptoms must have been present prior to age 12, must be present in two or more settings, must have clear evidence that they interfere with, or reduce the quality of, social, academic or occupational functioning, and must not occur exclusively within the course of schizophrenia or another psychiatric disorder.1
These are not the complete diagnostic criteria.
Diagnosis should be based on a complete history and evaluation of the patient.
While its exact cause is unknown, ADHD is thought to be the result of interactions between genetics, neurobiology, and the environment.6,7
The idea that an individual’s unique mix of genetic and environmental pressures influences disease pathology has given rise to a theory that an individual will manifest signs and symptoms of ADHD if and when their cumulative vulnerability exceeds a certain threshold.7 Based on numerous studies of twins, the mean heritability of ADHD has been estimated to be 77%, suggesting it to be among the most heritable of psychiatric disorders.6
Perinatal factors such as preterm birth, smoking and alcohol exposure during pregnancy, and low birth weight have been proposed as risk factors for ADHD.8,9 While the neurobiology of ADHD is not completely understood, it is thought that neurotransmitter dysfunction and dysregulation of various regions in the prefrontal cortex, as well as other areas of the brain, may be associated with symptoms of ADHD.10,11
As there is no cure for ADHD, the primary goal of ADHD management is to help address the core symptoms of inattention and/or hyperactivity-impulsivity.4
Each treatment plan should be individualized, comprehensive, and multimodal, taking into account available pharmacological and non-pharmacological therapies, education, and patient support resources.5 Periodic reassessments should be performed in order to monitor or assess the efficacy and safety of the treatment plan. Evaluation and management of ADHD should continue as long as symptoms are present and cause impairment of daily activities.
Annual meeting attracting the largest audience of psychiatrists and other mental health professionals offering opportunities to learn the latest in effective clinical practice, policy and research advancements.
Leading global conference discussing how to establish, incentivize, and share value sustainable for health systems, patients, and technology developers.
Global annual congress offering a platform for learning about the latest research advances and new treatments in neuropharmacology, psychiatry, and neuroscience.
Annual meeting bringing perspectives together from academia, NIH, FDA, clinicians and industry on key aspects of neuropsychiatric drug development, pharmacogenetics and personalized interventions.
Annual meeting bringing together healthcare professionals, scientists, advocates, industry representatives, and others who are working toward better outcomes for people with epilepsy.
Europe's premier meeting in applied and translational neuroscience discussing the latest developments in research, technologies and treatment of brain disorders.
Annual mental health conference bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, and other mental health professionals offering practical knowledge to improve patient care.
Meeting with a diverse group of stakeholders at the intersection of health care and policy to share important findings and latest research on how the health system works, what it costs, and how to improve it.
A national conference offering exclusive continuing education, legislative policy updates, hands-on workshops, lively exhibitors, and networking opportunities for the nurse practitioner community.
Annual meeting bringing perspectives together from academia, NIH, FDA, clinicians and industry on key aspects of neuropsychiatric drug development, pharmacogenetics and personalized interventions.
Annual congress offering scientific programs ranging from basic clinical sciences, psychiatric epidemiology, pharmacological and psychotherapies, to new digital technologies and understandings from related sciences such as anthropology, psychology and sociology.
Annual meeting attracting the largest audience of psychiatrists and other mental health professionals offering opportunities to learn the latest in effective clinical practice, policy and research advancements.
Global annual congress offering a platform for learning about the latest research advances and new treatments in neuropharmacology, psychiatry, and neuroscience.
Annual meeting in neurology promoting high quality patient-centric care in a variety of topics and specialties through various learning formats.
Annual congress to learn about new clinical tools, expand research frontiers, and explore innovative ideas for mental health care and prevention with a community of global professionals and stakeholders in psychiatry.
Medication Resources
(mixed salts of a single-entity amphetamine product), CII
(guanfacine)
(mixed salts of a single-entity amphetamine product), CII
(lisdexamfetamine dimesylate), CII